Merck KGaA expects tariff refunds for life science clients through 2026, with €40M included in guidance.
August 6, 2026 07:30 AM EDT
Merck KGaA readies tariff refunds worth €40M for life science customers
Merck KGaA said it expects to receive tariff refunds for its life science business through the end of 2026 after the US Supreme Court blocked …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
With Merck KGaA’s former electronics business lead Kai Beckmann now at the helm of the entire conglomerate, the new CEO is making…
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster…
Merck übernimmt den US-Laborausrüster Bio-Techne für 9,9 Milliarden – ein Zukauf, auf den Investoren und Analysten seit Jahren…
Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of…
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Revolution im Pharma-Labor: Für zehn Milliarden Euro kauft sich Merck in den Biotech-Boom ein
